Aarti Pharmalabs Ltd
Aarti Pharmalabs Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #25 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Aarti Pharmalabs Ltd Q2 FY27 key numbers
- Revenue
- The standalone revenue from operations (net) for the quarter was Rs. 61,258.69 lakhs compared to Rs. 41,728.78 lakhs in the corresponding quarter of the previous year, showing a similar growth trend.
As stated in Aarti Pharmalabs Ltd's Q2 FY27 results statement · published 29 Oct 2026. Reported figures, not investment advice.
Based on Aarti Pharmalabs Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For the quarter ended 30th September 2026, the consolidated revenue from operations (net) was Rs. For the quarter ended 30th Sept 2026, EBITDA reported is Rs.
From Aarti Pharmalabs Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.
Revenue & Sales Performance
- For the quarter ended 30th September 2026, the consolidated revenue from operations (net) was Rs. 61,045.10 lakhs, up from Rs. 41,833.48 lakhs in the quarter ended 30th September 2025, reflecting approximately a 46% year-on-year increase.
- The standalone revenue from operations (net) for the quarter was Rs. 61,258.69 lakhs compared to Rs. 41,728.78 lakhs in the corresponding quarter of the previous year, showing a similar growth trend.
- The company identifies only one segment: Pharmaceuticals.
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The financials reflect capital expenditures but without project descriptions.
- Other statements focus on financial results, audits, and management changes.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Aarti Pharmalabs Ltd said on order book & pipeline — free account, 30 seconds.
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹536 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharmalabs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sanofi Consumer Healthcare India Ltd (Q2 FY27)
Q3 2026 revenue: ₹2,631 million, a 12% year-on-year (Y-o-Y) growth. Key results statement takeaways from Sanofi Consumer Healthcare India Ltd's Q2 FY27 results
- Sudeep Pharma Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations:** Rs 196.7 crore . Key investor presentation takeaways from Sudeep Pharma Ltd's Q2 FY27 investor presentation — and how it rank
- Jagsonpal Pharmaceuticals Ltd (Q2 FY27)
Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY . Key investor presentation takeaways from Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation — and
- Zota Health Care Ltd (Q2 FY27)
Revenue from Operations for Q2FY27 is ₹19,933.14 lakhs, up 54.58% YoY from ₹12,894.82 lakhs in Q2FY26. Key investor presentation takeaways from Zota Health Care
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q2 FY27 results?
For the quarter ended 30th September 2026, the consolidated revenue from operations (net) was Rs. For the quarter ended 30th Sept 2026, EBITDA reported is Rs.
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 37.1 with a market cap of ₹7,994 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.